VYEPTI® (eptinezumab-jjmr) sponsored by Lundbeck


Resources for Your Practice
3 FILES

Physician Resources
Patient Resources
Getting VYEPTI
Indication

INDICATION

VYEPTI is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults

For more information, please see the Full Prescribing Information and Patient Information.

Dosage & Administration

DOSAGE AND ADMINISTRATION

  • Must dilute before use. For intravenous infusion only
  • Recommended dosage is 100 mg as an intravenous infusion over approximately 30 minutes every 3 months. Some patients may benefit from a dosage of 300 mg
  • Dilute only in 100 mL of 0.9% Sodium Chloride Injection, USP

DOSAGE FORMS AND STRENGTHS

Injection: 100 mg/mL solution in a single-dose vial

For more information, please see the Full Prescribing Information and Patient Information.

Contraindications

CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients

For more information, please see the Full Prescribing Information and Patient Information.

Warnings & Precautions

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: If a hypersensitivity reaction occurs, consider discontinuing VYEPTI and initiate appropriate therapy

For more information, please see the Full Prescribing Information and Patient Information.

Adverse Reactions

ADVERSE REACTIONS

The most common adverse reactions (≥2% and 2% or greater than placebo) were nasopharyngitis and hypersensitivity

To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at
1-800-455-1141 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For more information, please see the Full Prescribing Information and Patient Information.

© 2023 Lundbeck. All rights reserved. VYEPTI and VYEPTI GO are registered trademarks, and VYEPTI CONNECT and Migraine Victors Program are trademarks of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-101419

All trademarks, logo, and brand names are the property of their respective owners. All company, product, and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.

This website is intended for US healthcare professionals only.

For more information, please see the Full Prescribing Information and Patient Information.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

VYEPTI (eptinezumab-jjmr) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS 

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Full Prescribing Information and Patient Information.